| P2093 | author name string | Francis J Giles | |
| | Elias Jabbour | |
| P2860 | cites work | A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells | Q28119154 |
| | Proposals for the classification of the myelodysplastic syndromes | Q28275931 |
| | International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 |
| | Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice | Q28593600 |
| | Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 |
| | Myelodysplastic syndromes. | Q31131701 |
| | Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. | Q32061796 |
| | Pilot study of low-dose interleukin-11 in patients with bone marrow failure | Q33339598 |
| | Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes | Q33341182 |
| | Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes | Q33342598 |
| | Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes | Q33343522 |
| | Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome | Q33344880 |
| | Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome | Q33493683 |
| | RAS and leukemia: from basic mechanisms to gene-directed therapy | Q33539857 |
| | Myelodysplasia | Q33643119 |
| | A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. | Q33818649 |
| | Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? | Q33838981 |
| | KDR receptor: a key marker defining hematopoietic stem cells | Q33873300 |
| | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 |
| | Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. | Q34204305 |
| | Glutathione based approaches to improving cancer treatment | Q74811889 |
| | A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome | Q77476802 |
| | The Myelodysplastic Syndromes | Q77941420 |
| | Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow | Q78460549 |
| | Cytokines and MDS. | Q34434299 |
| | Applications of darbepoietin-alpha, a novel erythropoiesis-stimulating protein, in oncology | Q34601447 |
| | The myelodysplastic syndrome(s): a perspective and review highlighting current controversies | Q35044582 |
| | Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. | Q35186892 |
| | Epigenetic targets in hematopoietic malignancies | Q35551110 |
| | Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. | Q35571293 |
| | Novel therapies for myelodysplastic syndromes | Q35829958 |
| | Metalloproteinase-mediated release of human Fas ligand | Q36365559 |
| | Angiogenesis in myelodysplastic syndromes | Q36620007 |
| | Recent advances in biology and treatment of myelodysplasia | Q36653620 |
| | Treatment of acute myelogenous leukemia and myelodysplastic syndromes | Q40469779 |
| | Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia | Q40630235 |
| | Cellular differentiation, cytidine analogs and DNA methylation | Q42242732 |
| | Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) | Q43628961 |
| | Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. | Q43700135 |
| | Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes | Q43883722 |
| | Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene | Q44072019 |
| | Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome | Q44083618 |
| | Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta | Q44104227 |
| | Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. | Q44287656 |
| | A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life | Q44369408 |
| | SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes | Q44370169 |
| | Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report | Q44439895 |
| | Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders | Q44454011 |
| | Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting | Q44567748 |
| | Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 | Q44637369 |
| | Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies | Q44646952 |
| | Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome | Q44820387 |
| | Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor | Q45089956 |
| | Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT | Q45198892 |
| | World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. | Q46038765 |
| | Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia. | Q52546921 |
| | Myelodysplastic syndrome is not merely "preleukemia" | Q57700798 |
| | Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia | Q68559342 |
| | Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome | Q70802894 |
| | Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia | Q70893558 |
| | Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle | Q71249405 |
| | Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Tr | Q71519298 |
| | Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes | Q72344921 |
| | A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia | Q73005236 |
| | A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome | Q73581789 |
| | Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations | Q74121769 |
| | Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates | Q74171747 |
| | Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) | Q74346540 |
| | Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression | Q74412911 |
| | HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome | Q74605762 |
| P433 | issue | 1 | |
| P304 | page(s) | 25-33 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | New agents in myelodysplastic syndromes | |
| P478 | volume | 1 | |